Comparison of the Neuroprotective Effects of the N-Methyl-D-Aspartate Antagonist MK-801 and the Opiate-Receptor Antagonist Nalmefene in Experimental Spinal Cord Ischemia

Archives of Neurology

Volumn 47, Issue 3, 1990, Pages 277-281

  Yum, Sabrina W ^a   Faden, Alan I ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIZOCILPINE; N METHYLASPARTIC ACID; NALMEFENE; OPIATE ANTAGONIST;

ANIMAL MODEL; ARTICLE; HISTOLOGY; INTRAVENOUS DRUG ADMINISTRATION; MALE; MAMMAL; NONHUMAN; PRIORITY JOURNAL; RABBIT; SPINAL CORD ISCHEMIA;

ANIMAL; ASPARTIC ACID; COMPARATIVE STUDY; DIBENZOCYCLOHEPTENES; DIZOCILPINE MALEATE; HUMAN; ISCHEMIA; MALE; N-METHYLASPARTATE; NALTREXONE; NARCOTIC ANTAGONISTS; RABBITS; SPINAL CORD; SUPPORT, U.S. GOV'T, NON-P.H.S.; TIME FACTORS;

EID: 0025319344     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneur.1990.00530030043014     Document Type: Article

References (31)

1. Hosobuchi Y, Baskin WS, Woo SK. Reversal of induced ischemic neurologic deficit in gerbils by the opiate antagonist naloxone. Science. 1982;215:69-71.
2. Faden AI, Hallenbeck JM, Brown CQ. Treatment of experimental stroke: comparison of naloxone and thyrotropin-releasing hormone. Neurology. 1982;32:1083-1087.
3. Faden AI, Jacobs TP, Zivin JA. Comparison of naloxone and a delta-selective antagonist in experimental spinal 'stroke. Life Sci. 1983;33(suppl 1):707-710.
4. Faden AI. Role of thyrotropin-releasing hormone and opiate receptor antagonists in limiting central nervous system injury. Adv Neurol. 1987;47:531-545.
5. Faden AI, Jacobs TP. Opiate antagonist WIN44,441-3 stereospecifically improves neurologic recovery after ischemia spinal injury. Neurology. 1985;35:1311-1315.
6. Meldrum B. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters. Clin Sci. 1985;68:113-122.
7. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol. 1986;19:105-111.
8. Beneviste H, Drejer J, Schousboe A, Diemer NH. Elevation of the extracellular concentrations of glutamate and aspartate in rat hippocampus during transient cerebral ischemia monitored by intracerebral microdialysis. J Neurochem. 1984;43:1369-1374.
9. Hagberg H, Lehmann A, Sandberg M, Nystrom B, Jacobson I, Hamberger A. Ischemia-induced shift of inhibitory and excitatory amino acids from intra- to extracellular compartments. J Cereb Blood Flow Metab. 1985;5:413-419.
10. Simon RP, Swan JH, Griffiths T, Meldrum BS. Blockade of N-methyl-D-aspartate receptors may protect against ischemic damage in the brain. Science. 1984;226:850-852.
11. Nalmefene: Information for Physicians. Kenilworth, NJ: Key Pharmaceuticals Inc; 1984.
12. Michel ME, Bolger G, Weissman BA. Binding of a new opiate antagonist, nalmefene, to rat brain membranes. Pharmacologist. 1984;26:210.
13. Faden AI, Sacksen I, Noble LJ. Opiate-receptor antagonist nalmefene improves neurologic recovery after traumatic spinal cord injury in rats through a central mechanism. J Pharmacol Exp Ther. 1988;245:742-748.
14. Wong EHF, Kemp JA, Priestley T, Knight AR, Woodruff GN, Iversen LL. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci USA. 1986;83:7104-7108.
15. Faden AI, Lemke M, Simon RP, Noble LJ. N-methyl-D-aspartate antagonist MK801 improves outcome following traumatic spinal cord injury in rats: behavioral, anatomic, and neurochemical studies. J Neurotrauma. 1988;5:33-45.
16. Gill R, Foster AC, Woodruff GN. Systemic administration of MK-801 protects against ischemia-induced hippocampal neurodegeneration in the gerbil. J Neurosci. 1987;7:3343-3349.
17. Ozyurt E, Graham DI, Woodruff GN, McCulloch J. Protective effect of the glutamate antagonist, MK-801 in focal cerebral ischemia in the cat. J Cereb Blood Flow Metab. 1988;8:138-143.
18. Park CK, Nehls DG, Graham DI, Teasdale GM, McCulloch J. The glutamate antagonist MK-801 reduces focal ischemia brain damage in the rat. Ann Neurol. 1988;24:543-551.
19. Kochlar A, Zivin JA, Lyden PD, Mazzarella V. Glutamate antagonist therapy reduces neurologic deficits produced by focal central nervous system ischemia. Arch Neurol. 1988;44:148-153.
20. Boast CA, Gerhardt SC, Pastor G, Lehmann J, Etienne PE, Liebman JM. The N-methyl-D-aspartate antagonists CGS 19755 and CPP reduce ischemic brain damage in gerbils. Brain Res. 1988;442:345-348.
21. Gerhardt SC, Bernard P, Pastor G, Boast CA. Effects of systemic administration of the NMDA antagonist, CPP, on ischemic brain damage in gerbils. Soc Neurosci Abstr. 1986;12:59.
22. Faden AI, Jacobs TP, Smith MT, Zivin JA. Naloxone in experimental spinal cord ischemia: dose-response studies. Eur J Pharmacol. 1984;103:115-120.
23. Faden AI. Opioid and non-opioid mechanisms may contribute to dynorphin's pathophysiologic actions in spinal cord injury. Ann Neurol. In Press.
24. Chavkin C, James IF, Goldstein A. Dynorphin is a specific endogenous ligand for the κ-opioid receptor. Science. 1982;215:413-415.
25. Faden AI, Jacobs TP. Dynorphin-related peptides cause motor dysfunction in the rat through a non-opiate action. Br J Pharmacol. 1984;81:271-276.
26. Caudle RM, Isaac L. A novel interaction between dynorphin (1-13) and an N-methyl-D-aspartate site. Brain Res. 1988;443:329-332.
27. Bakshi R, Faden AI. Competitive and noncompetitive N-methyl-D-aspartate antagonists limit dynorphin A-induced rat hindlimb paralysis. Brain Res. In press.
28. Kim JP, Goldberg MP, Choi DW. High concentrations of naloxone attenuate N-methyl-D-aspartate receptor mediated neurotoxicity. Eur J Pharmacol. 1987;138:133-136.
29. Zivin JA, DeGirolami U. Spinal cord infarction: a highly reproducible stroke model. Stroke. 1980;11:200-202.
30. Cheng MK, Robertson C, Grossman RG, et al. Neurological outcome correlated with spinal evoked potentials in a spinal cord ischemia model. J Neurosurg. 1984;60:786-795.
31. McCullough JL, Hollier LH, Nugent M. Paraplegia after thoracic aortic occlusion: influence of cerebrospinal fluid drainage. J Vasc Surg. 1988;7:153-160.